Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
AssigneesIncyte Incorporation, Incyte Holdings Corporation
InventorsJincong Zhuo, Chunhong He, Wenqing Yao
Life of this patent
Estimating the term…
Abstract
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
Claims18
A method of treating a hematopoietic malignancy, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, or melanoma associated with dysregulation of the HGF/c-MET signaling pathway in a patient, comprising administering to said patient a therapeutically effective amount of a compound, selected from
- 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- and
- 2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- or a pharmaceutically acceptable salt of any of the aforementioned.
A method of treating a hematopoietic malignancy, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer or melanoma in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from
- 2-fluoro-N-[(2R)-2-hydroxypropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- and
- 2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]3-3-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- or a pharmaceutically acceptable salt of any of the aforementioned.
A method of treating a hematopoietic malignancy, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer or melanoma in a patient comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from
- 2-fluoro-N-[(2R)-2-hydroxypropyI]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- and
- 2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]3-3-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
- or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.